Bachem and ILS extend their collaboration in Japan by an Exclusive Agency Agreement

September 07, 2015

Bubendorf/Basel, Switzerland and Ibaraki, Japan, September 7th, 2015 – Bachem (SIX: BANB) and ILS announce today that they will strengthen their co-marketing efforts in Japan. The two companies have been establishing a close collaboration for more than a decade, already. Based on a Sales and Marketing agreement which was signed in 2012, ILS is providing Bachem manufactured Active Pharmaceutical Ingredients (API) to Japanese customers. In the course of the acquisition of American Peptide Company, Inc. (APC), based in California USA, and its transfer from ILS to Bachem, both companies underlined their intentions to extend the current business relations. Under the agreement reached, ILS will be the Exclusive Agent for Japan for all peptide-based products of the Bachem Group; this applies to non-GMP research chemicals as well as for cGMP grade API. In addition, ILS will register Drug Master Files in Japan for API manufactured by Bachem.


At Bachem, we believe that our employees make the difference. Representing our corporate culture of passion and commitment, they are the foundation of our success. We therefore strive to attract, retain, and develop highly motivated, well-qualified individuals.

View all jobs

Click here >>

Contact us


  • Fields marked with an asterisk (*) are required

  • Hidden
  • Hidden
  • This field is for validation purposes and should be left unchanged.